Funding: The study was supported by a Project Grant from the National Heart Foundation of New Zealand and the Cardiovascular Ultrasound Laboratory has received financial support from the New Zealand Lotteries Board. K. K. P. is the recipient of a postgraduate scholarship from the National Heart Foundation of New Zealand. J. B. S. was supported by the Douglas Goodfellow Medical Research Fellowship, the Auckland Medical Research Foundation and the Green Lane Research and Educational Fund.
Role of echocardiographic left ventricular mass and carotid intima-media thickness in the cardiovascular risk assessment of asymptomatic patients with type 2 diabetes mellitus
Article first published online: 14 JUL 2010
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians
Internal Medicine Journal
Volume 41, Issue 5, pages 391–398, May 2011
How to Cite
Poppe, K. K., Whalley, G. A., Somaratne, J. B., Keelan, S., Bagg, W., Triggs, C. M. and Doughty, R. N. (2011), Role of echocardiographic left ventricular mass and carotid intima-media thickness in the cardiovascular risk assessment of asymptomatic patients with type 2 diabetes mellitus. Internal Medicine Journal, 41: 391–398. doi: 10.1111/j.1445-5994.2010.02305.x
Conflict of interest: None.
- Issue published online: 23 MAY 2011
- Article first published online: 14 JUL 2010
- Accepted manuscript online: 14 JUL 2010 12:00AM EST
- Received 8 April 2010; accepted 8 June 2010.
- risk assessment;
- carotid arteries;
- left ventricular hypertrophy;
- type 2 diabetes mellitus
Background: Standard cardiovascular (CV) risk assessment may underestimate risk in people with type 2 diabetes mellitus (T2DM). Cardiac and vascular imaging to detect subclinical disease may augment risk prediction. This study investigated the association between CV risk, left ventricular hypertrophy (LVH) and carotid intima-media thickness (CIMT) in patients with T2DM free of CV symptoms.
Methods: People with T2DM without known CV disease were recruited from general practice. The 5-year risk of CV events was calculated using an adjusted Framingham equation and the prevalence of LVH and abnormal CIMT across bands of CV risk assessed. In those at intermediate risk, the number needed to scan (NNS) to reclassify one person to high risk was calculated across the group and compared in those above and below 55 years. The association between LV mass and CIMT was also assessed.
Results: Mean age 57 years (SD11), 51% female. Median 5-year CV risk 14.3% (interquartile range 10.3, 19.5), 51% had LVH (American Society of Echocardiography criteria) and 31% an abnormal CIMT (age and sex criteria). In the 52% at intermediate risk, 37% had LVH and 36% an abnormal CIMT. The NNS was 1.7 using both imaging techniques, 2.7 using cardiac imaging alone or 2.8 using vascular imaging alone. Almost twice as many people >55 years had an abnormal CIMT than those <55 years.
Conclusions: Cardiac and vascular imaging to detect subclinical disease can be used to augment prediction of CV risk in people with T2DM at intermediate risk. The value of reclassifying risk is as yet unproven and requires outcome data from intervention studies.